Physician profile
Michael D Baum
NPI 1689662140
$1,320.08
in general payments reported to CMS, 2019-2025
16 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $569 · 2020: $73.68 · 2021: $470 · 2022: $181 · 2024: $26.54.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $26.54.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $26.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Notal Vision, INC. | $247.00 | 2021 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $194.73 | 2019-2021 | |
| Allergan, INC. | $182.77 | 2019-2021 | |
| Aerie Pharmaceuticals, INC. | $151.82 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $119.06 | 2019-2022 | |
| Sun Pharmaceutical Industries INC. | $95.51 | 2019-2021 | |
| Oyster Point Pharma, INC. | $67.99 | 2022 | |
| Dompe US, INC. | $52.09 | 2019-2021 | |
| Shire North American Group INC | $45.34 | 2019 | |
| Bausch & Lomb Americas INC. | $35.22 | 2022 | |
| Amgen INC. | $26.54 | 2024 | Tepezza |
| Abbvie INC. | $26.25 | 2022 | |
| Kala Pharmaceuticals, INC. | $24.24 | 2019 | |
| Johnson & Johnson Vision Care, INC. | $23.64 | 2019-2020 | |
| Alcon Vision LLC | $16.66 | 2022 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eyevance Pharmaceuticals LLC | $11.22 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Baum listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.